BD Reaches Major Milestone with 1,000th Rhapsody System
BD Achieves Milestone with Rhapsody System
BD (Becton, Dickinson and Company) (NYSE: BDX), a prominent name in medical technology, has proudly announced the installation of its 1,000th BD Rhapsody™ System. This remarkable instrument is key to facilitating single-cell multiomics analysis and is now operational at Addenbrooke's Hospital associated with a distinguished university. The BD Rhapsody™ System, equipped with diverse assays to analyze DNA, RNA, and proteins, empowers researchers to glean detailed insights from numerous individual cells concurrently.
Revolutionizing Scientific Research
Dr. Andrew Conway Morris, a prominent associate professor at Addenbrooke's, emphasizes the significant role this technology plays in his research. His team focuses on exploring the signaling pathways of immune cells and their contributions to patient inflammation, particularly in those requiring intensive care. The BD Rhapsody™ System enables them to conduct multiomic data analysis in a seamless manner, allowing for the exploration of biological processes at a single-cell resolution. This innovation aims to transform research discoveries into effective treatment strategies for critically ill patients, offering new hope and strategies for recovery.
Significant Publication Impact
Since its launch in 2017, the BD Rhapsody™ instrument has been referenced in over 700 research articles published in recognized peer-reviewed journals. The latest iteration, introduced in 2023, features cutting-edge technology for sample processing and cell capture, utilizing a gentle, reliable microwell-based cartridge system enhanced by BD’s proprietary molecular indexing technology. Researchers can now develop various library types for next-generation sequencing at an accelerated pace, resulting in quicker insights.
Uniquely Positioned in Multiomics
The BD Rhapsody™ System is strategically integrated into the workflow of cell sorting and analysis. It works synergistically with the BD FACSDiscover™ S8 Cell Sorter and A8 Cell Analyzer, providing a comprehensive solution that caters to today's scientific demands. Ranga Partha, PhD, VP of Global Marketing at BD Biosciences, remarks that this milestone showcases the essential need for a high-performance single-cell platform that maintains data integrity without incurring excessive costs per analysis.
Future Innovations on the Horizon
BD is not resting on its laurels. The company is committed to enhancing the BD Rhapsody™ System and its capabilities. Upcoming innovations include:
New Assays and Automation
- The launch of the BD OMICS-One™ WTA Next Assay aims to support early-access customers in retrieving more genetic data from individual cells affordably.
- BD® OMICS-Guard Cryo will debut soon, enabling long-term sample preservation and analysis batching.
- Enhanced automation solutions are being developed to optimize and expedite workflows for researchers.
Dr. Andrew Conway Morris's innovative research receives funding from several esteemed entities, further underlining the importance of this work. In the near future, the BD Rhapsody™ System will be showcased at various scientific gatherings, highlighting its pivotal role in human genetics.
About BD
BD is among the largest global medical technology firms, dedicated to enhancing health outcomes through advancements in medical research, diagnostics, and care delivery. The company, backed by a passionate workforce exceeding 70,000, develops transformative technologies and services aimed at improving clinical therapies and streamlining healthcare processes. BD partners with organizations worldwide to confront pressing health issues, ensuring safer and more efficient healthcare delivery. Discover more about BD through their primary website or connect with them across social media platforms.
Frequently Asked Questions
What is the significance of the 1,000th Rhapsody System placement?
This milestone reflects BD's commitment to advancing single-cell multiomics technology and its role in significant medical research.
How does the BD Rhapsody System improve single-cell analysis?
It allows researchers to analyze multiomic data efficiently, enhancing biological insights into single-cell levels.
What future developments can we expect from BD?
BD plans to launch new assays and advanced automation solutions to streamline workflows for researchers.
Who funds Dr. Conway Morris's research?
The research is supported by several organizations, including the Medical Research Council and LifeArc.
How can BD's technologies benefit healthcare providers?
BD’s technologies enhance diagnostic capabilities, leading to improved patient outcomes and streamlined clinical processes.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
